Patent Expiry

Patent/Exclusivity Expiry: AKYNZEO

Other upcoming events for HRTX

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801
Patent ExpiryPatent/Exclusivity Expiry: FOCINVEZ

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: AKYNZEO — HRTX Patent Expiry | BioSniper